✦ LIBER ✦

Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease

✍ Scribed by Stephan R. Targan; Brian G. Feagan; Severine Vermeire; Remo Panaccione; Gil Y. Melmed; Consuelo Blosch; Richard Newmark; Nan Zhang; Yun Chon; Shao-Lee Lin; Paul Klekotka

Book ID: 119762322
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 89 KB
Volume: 143
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2012.07.084

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Moderate to Severe Asthma

✍ Busse, William W.; Holgate, Stephen T.; Kerwin, Edward M.; Chon, Yun; Feng, Jing 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 38 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

Fontolizumab in moderate to severe Crohn

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

✍ Walter Reinisch; Williem de Villiers; László Bene; László Simon; István Rácz; Se 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB

## Background: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptom

A 24-week, randomized, double-blind, pla

A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease

✍ Nakamura, Yu; Imai, Yukimichi; Shigeta, Masahiro; Graf, Ana; Shirahase, Toru; Ki 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 54 KB

A phase I, double-blind, placebo-control

A phase I, double-blind, placebo-controlled, randomized, multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of PF 04447943 in mild-to-moderate Alzheimer's disease subjects on stable donepezil therapy

✍ Evans, Rebecca; Nicholas, Timothy; Le, Vu; Martin, William; Martin, David; Schwa 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 51 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

✍ A.B. Gottlieb; R.G. Langley; B.E. Strober; K.A. Papp; P. Klekotka; K. Creamer; E 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 322 KB